Trv Gp V LLC Invests $208.16 Billion in Septerna, Inc. $SEPN

Trv Gp V LLC acquired a new stake in Septerna, Inc. (NASDAQ:SEPN) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 6,215,591 shares of the company’s stock, valued at approximately $208,160,143,000. Septerna comprises approximately 41.8% of Trv Gp V LLC’s investment portfolio, making the stock its 2nd biggest holding. Trv Gp V LLC owned approximately 0.14% of Septerna as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Group One Trading LLC grew its stake in Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after purchasing an additional 8,955 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in Septerna during the 4th quarter worth about $35,000. Russell Investments Group Ltd. acquired a new stake in Septerna in the 3rd quarter valued at about $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Septerna in the 4th quarter valued at about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Septerna in the 4th quarter valued at about $61,000.

Insider Activity at Septerna

In other Septerna news, insider Samira Shaikhly sold 11,798 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the transaction, the insider directly owned 793 shares in the company, valued at $23,837.58. This represents a 93.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Daniel D. Long sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total transaction of $532,650.00. Following the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,423,590.12. The trade was a 13.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 72,828 shares of company stock valued at $2,684,314 over the last three months. 5.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on SEPN shares. Wells Fargo & Company boosted their price objective on Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. HC Wainwright raised their target price on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. JonesTrading boosted their price target on shares of Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. Finally, Truist Financial lifted their price objective on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.33.

Septerna Stock Performance

NASDAQ:SEPN opened at $43.80 on Wednesday. The stock has a 50-day simple moving average of $36.37 and a 200-day simple moving average of $29.94. The stock has a market cap of $2.04 billion, a P/E ratio of -81.11 and a beta of 2.29. Septerna, Inc. has a 1 year low of $10.74 and a 1 year high of $51.10.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The business had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. On average, equities research analysts predict that Septerna, Inc. will post -1.36 EPS for the current year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.